INTRODUCTION: Fibrinolytics such as recombinant tissue plasminogen activator (rt-PA) are used to treat thrombotic disease such as acute myocardial infarction (AMI) and ischemic stroke. Interest in increasing efficacy and reducing side effects has led to the study of adjuncts such as GP IIb-IIIa inhibitors and ultrasound (US) enhanced thrombolysis. Currently, GP IIb-IIIa inhibitor and fibrinolytic treatment are often used in AMI, and are under investigation for stroke treatment. However, little is known of the efficacy of combined GP IIb-IIIa inhibitor, fibrinolytic and ultrasound treatment. We measure the lytic efficacy of rt-PA, eptifibatide (Epf) and 120 kHz ultrasound treatment in an in-vitro human clot model. MATERIALS AND METHODS: Blood was drawn from 15 subjects after IRB approval. Clots were made in 20 microL pipettes, and placed in a water tank for microscopic visualization during lytic treatment. Clots were exposed to control, rt-PA (rt-PA), eptifibatide (Epf), or rt-PA+eptifibatide (rt-PA + Epf), with (+US) or without (-US) ultrasound for 30 minutes at 37 degrees C in human plasma. Clot lysis was measured over time, using a microscopic imaging technique. The fractional clot loss (FCL) and initial lytic rate (LR) were used to quantify lytic efficacy. RESULTS AND CONCLUSIONS: LR values for (- US) treated clots were 0.8+/-0.1(control), 1.8+/-0.3 (Epf), 1.5+/-0.2 (rt-PA), and 1.3+/-0.4 (rt-PA + Epf) (% clot width/minute) respectively. In comparison, the (+ US) group exhibited LR values of 1.6+/-0.2 (control), 4.3+/-0.4 (Epf), 6.3+/-0.4 (rt-PA), and 4.6+/-0.6 (rt-PA + Epf). For (- US) treated clots, FCL was 6.0+/-0.8 (control), 9.2+/-2.5 (Epf), 15.6+/-1.7 (rt-PA), and 28.0+/-2.2% (rt-PA + Epf) respectively. FCL for (+ US) clots was 13.5+/-2.4 (control), 20.7+/-6.4 (Epf), 44.4+/-3.6 (rt-PA) and 30.3+/-3.6% (rt-PA + Epf) respectively. Although the addition of eptifibatide enhances the in-vitro lytic efficacy of rt-PA in the absence of ultrasound, the efficacy of ultrasound and rt-PA is greater than that of combined ultrasound, rt-PA and eptifibatide exposure.
INTRODUCTION: Fibrinolytics such as recombinant tissue plasminogen activator (rt-PA) are used to treat thrombotic disease such as acute myocardial infarction (AMI) and ischemic stroke. Interest in increasing efficacy and reducing side effects has led to the study of adjuncts such as GP IIb-IIIa inhibitors and ultrasound (US) enhanced thrombolysis. Currently, GP IIb-IIIa inhibitor and fibrinolytic treatment are often used in AMI, and are under investigation for stroke treatment. However, little is known of the efficacy of combined GP IIb-IIIa inhibitor, fibrinolytic and ultrasound treatment. We measure the lytic efficacy of rt-PA, eptifibatide (Epf) and 120 kHz ultrasound treatment in an in-vitro human clot model. MATERIALS AND METHODS: Blood was drawn from 15 subjects after IRB approval. Clots were made in 20 microL pipettes, and placed in a water tank for microscopic visualization during lytic treatment. Clots were exposed to control, rt-PA (rt-PA), eptifibatide (Epf), or rt-PA+eptifibatide (rt-PA + Epf), with (+US) or without (-US) ultrasound for 30 minutes at 37 degrees C in human plasma. Clot lysis was measured over time, using a microscopic imaging technique. The fractional clot loss (FCL) and initial lytic rate (LR) were used to quantify lytic efficacy. RESULTS AND CONCLUSIONS:LR values for (- US) treated clots were 0.8+/-0.1(control), 1.8+/-0.3 (Epf), 1.5+/-0.2 (rt-PA), and 1.3+/-0.4 (rt-PA + Epf) (% clot width/minute) respectively. In comparison, the (+ US) group exhibited LR values of 1.6+/-0.2 (control), 4.3+/-0.4 (Epf), 6.3+/-0.4 (rt-PA), and 4.6+/-0.6 (rt-PA + Epf). For (- US) treated clots, FCL was 6.0+/-0.8 (control), 9.2+/-2.5 (Epf), 15.6+/-1.7 (rt-PA), and 28.0+/-2.2% (rt-PA + Epf) respectively. FCL for (+ US) clots was 13.5+/-2.4 (control), 20.7+/-6.4 (Epf), 44.4+/-3.6 (rt-PA) and 30.3+/-3.6% (rt-PA + Epf) respectively. Although the addition of eptifibatide enhances the in-vitro lytic efficacy of rt-PA in the absence of ultrasound, the efficacy of ultrasound and rt-PA is greater than that of combined ultrasound, rt-PA and eptifibatide exposure.
Authors: Stefan Pfaffenberger; Branka Devcic-Kuhar; Christian Kollmann; Stefan P Kastl; Christoph Kaun; Walter S Speidl; Thomas W Weiss; Svitlana Demyanets; Robert Ullrich; Heinz Sochor; Christian Wöber; Josef Zeitlhofer; Kurt Huber; Martin Gröschl; Ewald Benes; Gerald Maurer; Johann Wojta; Michael Gottsauner-Wolf Journal: Stroke Date: 2004-12-09 Impact factor: 7.914
Authors: Abdallah G Rebeiz; Per Johanson; Cindy L Green; Suzanne W Crater; Matthew T Roe; Anatoly Langer; Robert P Giugliano; A Michael Lincoff; L Kristin Newby; Robert A Harrington; Eric J Topol; Robert M Califf; Galen S Wagner; Mitchell W Krucoff Journal: Am J Cardiol Date: 2005-03-01 Impact factor: 2.778
Authors: D Tanne; V E Bates; P Verro; S E Kasner; J R Binder; S C Patel; H H Mansbach; S Daley; L R Schultz; P N Karanjia; P Scott; J M Dayno; K Vereczkey-Porter; C Benesch; D Book; W M Coplin; D Dulli; S R Levine Journal: Neurology Date: 1999-07-22 Impact factor: 9.910
Authors: Clinton D Protack; Andrew M Bakken; Nikhil Patel; Wael E Saad; David L Waldman; Mark G Davies Journal: J Vasc Surg Date: 2007-05 Impact factor: 4.268
Authors: Jason M Meunier; Christy K Holland; Tyrone M Porter; Christopher J Lindsell; George J Shaw Journal: Curr Neurovasc Res Date: 2011-11 Impact factor: 1.990
Authors: Kathryn E Hitchcock; Nikolas M Ivancevich; Kevin J Haworth; Danielle N Caudell Stamper; Deborah C Vela; Jonathan T Sutton; Gail J Pyne-Geithman; Christy K Holland Journal: Ultrasound Med Biol Date: 2011-08 Impact factor: 2.998
Authors: Madhuvanthi A Kandadai; Jason Meunier; Christopher J Lindsell; George J Shaw; Mitchell S V Elkind Journal: Curr Neurovasc Res Date: 2012-08 Impact factor: 1.990
Authors: George J Shaw; Jason M Meunier; Christopher J Lindsell; Arthur M Pancioli; Christy K Holland Journal: Thromb Res Date: 2010-09-01 Impact factor: 3.944
Authors: Susan T Laing; Melanie R Moody; Hyunggun Kim; Beverly Smulevitz; Shao-Ling Huang; Christy K Holland; David D McPherson; Melvin E Klegerman Journal: Thromb Res Date: 2011-11-30 Impact factor: 3.944
Authors: Madhuvanthi A Kandadai; Jason M Meunier; Kimberley Hart; Christy K Holland; George J Shaw Journal: Transl Stroke Res Date: 2014-11-20 Impact factor: 6.829
Authors: George J Shaw; Jason M Meunier; Shao-Ling Huang; Christopher J Lindsell; David D McPherson; Christy K Holland Journal: Thromb Res Date: 2009-02-13 Impact factor: 3.944